These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19466906)

  • 1. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
    Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
    J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
    Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
    Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer.
    Standaert TA; Vandevanter D; Ramsey BW; Vasiljev M; Nardella P; Gmur D; Bredl C; Murphy A; Montgomery AB
    J Aerosol Med; 2000; 13(2):147-53. PubMed ID: 11010595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
    Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
    Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems.
    Mashat M; Clark BJ; Assi KH; Chrystyn H
    Pulm Pharmacol Ther; 2016 Apr; 37():37-42. PubMed ID: 26747025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
    Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
    Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
    Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
    Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
    van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
    Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers.
    Coates AL; MacNeish CF; Lands LC; Meisner D; Kelemen S; Vadas EB
    Chest; 1998 Apr; 113(4):951-6. PubMed ID: 9554630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.
    Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW
    Int J Pharm; 1999 Nov; 189(2):205-14. PubMed ID: 10536249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.
    Elhissi AM; Karnam KK; Danesh-Azari MR; Gill HS; Taylor KM
    J Pharm Pharmacol; 2006 Jul; 58(7):887-94. PubMed ID: 16805947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects.
    Lenney W; Edenborough F; Kho P; Kovarik JM
    J Cyst Fibros; 2011 Jan; 10(1):9-14. PubMed ID: 20884302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures.
    Elhissi AM; Faizi M; Naji WF; Gill HS; Taylor KM
    Int J Pharm; 2007 Apr; 334(1-2):62-70. PubMed ID: 17123757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
    Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
    J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser.
    de Boer AH; Hagedoorn P; Frijlink HW
    Int J Pharm; 2003 Dec; 268(1-2):59-69. PubMed ID: 14643977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal evaluation of compressor/nebulizer performance.
    Awad S; Williams DK; Berlinski A
    Respir Care; 2014 Jul; 59(7):1053-61. PubMed ID: 24149670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.